285 related articles for article (PubMed ID: 17145519)
1. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.
Ellis LM
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S1-7. PubMed ID: 17145519
[TBL] [Abstract][Full Text] [Related]
2. [New medications; bevacizumab].
Cohen AF; van Bronswijk H
Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
[TBL] [Abstract][Full Text] [Related]
3. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Collins TS; Hurwitz HI
Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
[TBL] [Abstract][Full Text] [Related]
4. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer.
Grothey A
Semin Oncol; 2006 Oct; 33(5 Suppl 10):S41-9. PubMed ID: 17145524
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
Boige V; Malka D; Ducreux M
Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667
[TBL] [Abstract][Full Text] [Related]
6. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
7. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy.
Dickson PV; Hamner JB; Sims TL; Fraga CH; Ng CY; Rajasekeran S; Hagedorn NL; McCarville MB; Stewart CF; Davidoff AM
Clin Cancer Res; 2007 Jul; 13(13):3942-50. PubMed ID: 17606728
[TBL] [Abstract][Full Text] [Related]
9. VEGF as a therapeutic target in cancer.
Ferrara N
Oncology; 2005; 69 Suppl 3():11-6. PubMed ID: 16301831
[TBL] [Abstract][Full Text] [Related]
10. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer.
Chase JL
Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
Abbadessa G; Vogiatzi P; Rimassa L; Claudio PP
Drug News Perspect; 2007 Jun; 20(5):307-13. PubMed ID: 17878958
[TBL] [Abstract][Full Text] [Related]
12. Targeting angiogenesis in cancer: clinical development of bevacizumab.
Kerr DJ
Nat Clin Pract Oncol; 2004 Nov; 1(1):39-43. PubMed ID: 16264798
[TBL] [Abstract][Full Text] [Related]
13. The horizon of antiangiogenic therapy for colorectal cancer.
Olszewski AJ; Grossbard ML; Kozuch PS
Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
[TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibitors in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Semin Oncol; 2004 Dec; 31(6 Suppl 17):10-6. PubMed ID: 15696025
[TBL] [Abstract][Full Text] [Related]
15. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer.
Fakih M
Expert Rev Anticancer Ther; 2013 Apr; 13(4):427-38. PubMed ID: 23432698
[TBL] [Abstract][Full Text] [Related]
16. Recent concepts of antiangiogenic therapy.
Konno H; Yamamoto M; Ohta M
Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
Goldberg RM; Hurwitz HI; Fuchs CS
Clin Adv Hematol Oncol; 2005 Dec; 3(12):1-10; quiz 11. PubMed ID: 16555433
[TBL] [Abstract][Full Text] [Related]
18. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
19. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
20. The present and future of angiogenesis-directed treatments of colorectal cancer.
O'Dwyer PJ
Oncologist; 2006 Oct; 11(9):992-8. PubMed ID: 17030640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
